developed second-generation HER2-CAR-T cells and investigated their administration via intravenous, local intratumoral, and regional intraventricular routes in preclinical settings using human xenograft models of HER2-positive breast cancer with brain metastases. The gene discussed is ERBB2; the disease is breast cancer.